- 17 October 2023
- book chapter
- Published by Springer Nature
- p. 93-99
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).Journal of Clinical Oncology, 2022
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate CancerNew England Journal of Medicine, 2021
- Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMAEuropean Urology, 2021
- The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginningIndian Journal of Urology, 2020
- Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand TherapyJournal of Nuclear Medicine, 2019
- [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyThe Lancet Oncology, 2018
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor ControlJournal of Nuclear Medicine, 2018